Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
NCT00045227
Completed
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of vaccine therapy with or without docetaxel in treating patients who have metastatic prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/18/2013
Locations: Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland
Conditions: Prostate Cancer
Register for Updates
Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer
NCT00052351
Completed
RATIONALE: Vaccines made from a gene-modified virus may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with sargramostim and chemotherapy may kill more tumor cells. PURPOSE: Randomized clinical trial to study the effectiv... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/17/2013
Locations: Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland +1 locations
Conditions: Breast Cancer
Register for Updates
Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00006041
Completed
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill the tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have ovarian, fallopian tube, or peritoneal cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/17/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
Combined Modality Treatment for Patients With Stage IV Melanoma
NCT00313235
Completed
The purpose of this study is to test a combined treatment using cyclophosphamide and a novel dendritic cell vaccine in patients with Stage IV melanoma.
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
06/12/2013
Locations: Baylor University Medical Center, Dallas, Texas
Conditions: Malignant Melanoma Stage IV
Register for Updates
SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells
NCT00091130
Completed
This randomized phase II trial is studying how well SGN-00101 vaccine works compared to a placebo in treating human papillomavirus and preventing cervical cancer in patients with abnormal cervical cells. Vaccines, such as SGN-00101, may make the body build an immune response to kill human papillomavirus and abnormal cervical cells and may be effective in preventing cervical cancer
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
05/31/2013
Locations: University of California Medical Center At Irvine-Orange Campus, Orange, California
Conditions: Atypical Squamous Cells of Undetermined Significance, Cervical Cancer, High-grade Squamous Intraepithelial Lesion, Low-grade Squamous Intraepithelial Lesion
Register for Updates
H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults
NCT00310206
Completed
The purpose of this research study is to compare how the body reacts to different strengths of an H5N1 flu vaccine when given by different routes of injection (injection into the skin or into the muscle). It will also compare how antibodies (proteins produced by the body's immune system that recognize and help fight infections and other foreign substances in the body) are made after receiving the H5N1 flu vaccine. Participants will include 100 healthy adults, ages 18-40 years. Study procedures i... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
05/30/2013
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Influenza
Register for Updates
Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery
NCT00016133
Completed
RATIONALE: Vaccines made from a patient's white blood cells and tumor cells may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy combined with leucovorin and fluorouracil in treating patients who have undergone surgery to completely rem... Read More
Gender:
ALL
Ages:
Between 21 years and 85 years
Trial Updated:
05/29/2013
Locations: John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital, Allentown, Pennsylvania +1 locations
Conditions: Colorectal Cancer
Register for Updates
Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults
NCT01430819
Completed
The aim of the study is to evaluate the safety and immunogenicity of the 2011-2012 formulation of Fluzone and Fluzone High-Dose vaccines in participants aged 65 years and older. Objectives: * To describe the safety of Fluzone vaccine and Fluzone High-Dose vaccine among adults ≥ 65 years of age. * To describe the immunogenicity of Fluzone vaccine and Fluzone High-Dose vaccine among adults ≥ 65 years of age.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/16/2013
Locations: Not set, Colorado Springs, Colorado +5 locations
Conditions: Influenza
Register for Updates
Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer
NCT00009958
Terminated
Phase I trial to compare the effectiveness of vaccine therapy with or without sargramostim in treating patients who have solid tumors. Vaccines may make the body build an immune response to kill tumor cells. Combining colony-stimulating factors such as sargramostim with vaccines may kill more tumor cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2013
Locations: Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer
NCT00601796
Completed
The purpose of this study is to find out what effects (good and/or bad) a tumor vaccine used in combination with two drugs (ATRA and cytoxan) have on the patient and their cancer. We also want to find out if the vaccine and the drugs can boost the patient's immune system and how their immune system reacts, both before and after the vaccine treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2013
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Lung Cancer
Register for Updates
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
NCT00806195
Completed
The primary objective of this phase 3b study is to evaluate the safety and tolerability of Novartis MenACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants
Gender:
ALL
Ages:
Between 55 days and 89 days
Trial Updated:
05/13/2013
Locations: 6 Alabama Clinical Therapeutics 806 St. Vincent's Drive, Ste 615, Birmingham, Alabama +152 locations
Conditions: Meningitis, Meningococcal Infection
Register for Updates
Optimizing Influenza Vaccination in Surgical Oncology Patients
NCT01698177
Unknown
Seasonal influenza (flu) is a significant and sometimes serious health issue in the U.S. The Centers for Disease Control (CDC) estimates that over 200,000 people are hospitalized in the U.S each year related to the flu. Public health campaigns advocate widespread vaccination for the flu, and especially for high risk people. People with cancer are high risk, with an increased risk of developing complications from the flu, such as pneumonia, bronchitis, or worsening of other medical conditions. As... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2013
Locations: Stony Brook Hospital, Stony Brook, New York
Conditions: Influenza
Register for Updates